Phototherapy: The patients' point of view-Reference-Cited by-同舟云学术

Phototherapy: The patients' point of view

Published:2020-12-05 Issue:2 Volume:37 Page:175-179
ISSN:0905-4383
Container-title:Photodermatology, Photoimmunology & Photomedicine
language:en
Short-container-title:Photodermatol. Photoimmunol. Photomed.

Author:

Odorici Giulia¹,Di Nuzzo Sergio²,Corazza Monica¹,Bardazzi Federico³,Cortelazzi Chiara⁴^ORCID,Sacchelli Lidia³,Conti Andrea⁴^ORCID

Affiliation:

1. Section of Dermatology and Infectious Diseases Department of Medical Sciences University of Ferrara Ferrara Italy

2. Dermatology Department of Medicine and Surgery University of Parma Parma Italy

3. Department of Experimental, Diagnostic and Specialty Medicine‐ Division of Dermatology University of Bologna Bologna Italy

4. Dermatology Unit Department of Surgical Medical, Dental and Morphological Sciences, Transplant, Oncological and Regenerative Medicine University of Modena and Reggio Emilia Modena Italy

Publisher

Wiley

Subject

Dermatology,Radiology Nuclear Medicine and imaging,Immunology,General Medicine,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/phpp.12629

Reference11 articles.

1. Phototherapy achieves significant cost savings by the delay of drug‐based treatment in psoriasis

2. Role of phototherapy in the era of biologics;Torres AE;J Am Acad Dermatol,2020

3. Systematic Review of UV-Based Therapy for Psoriasis

4. Phototherapy;Singer S;J Dtsch Dermatol Ges,2018

5. Peeking into immunoregulatory effects of phototherapy

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The clinical spectrum of response to narrowband‐UVB therapy in chronic plaque psoriasis: The lower limbs are the most difficult‐to‐treat body region;Photodermatology, Photoimmunology & Photomedicine;2023-05

2. Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching;Pharmaceuticals;2022-01-14